Dr. Markus Keussen, CEO of medifa GmbH and at the same time CEO of the parent company Reinsberg Group, will focus more on the management of the Reinsberg Group from December 1, 2024. In November 2024, the European MedTech Group finalized its fourth acquisition with Brandon Medical in the UK within 3 years and has thus grown to almost 100m euros in sales. Future growth and the realization of further acquisitions require Dr. Keussen's full attention.

The current CSO of medifa GmbH, Mr. Magnus Rüding, will be appointed CEO of the Finnentrop-based MedTech company from December 1, 2024. Mr. Rüding has made a significant contribution to ensuring that medifa GmbH will end 2024 as its most successful financial year.

Dr. Keussen will remain with medifa GmbH as a board member.